Cocrystal Pharma completes dosing in Phase 1b norovirus challenge study for CDI-988

Cocrystal Pharma, Inc.

Last subject dosed in Phase 1b norovirus challenge study (NCT07198139) evaluating CDI-988 as preventive and treatment.
No serious adverse events reported to date; CDI-988 previously safe at 1200 mg dose in Phase 1.
Preliminary efficacy results expected late 2026 or early 2027.
Study at Emory University enrolled healthy adults 18-49 infected with GII.2 (Snow Mountain Virus) strain.
CDI-988 is first oral antiviral for norovirus, designed to inhibit replication in all known strains.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.